Get the Stockscreener App
8.35
7.63%
-0.69
After Hours:
8.35
Lexeo Therapeutics Inc stock is traded at $8.35, with a volume of 2.99M.
It is down -7.63% in the last 24 hours and up +26.13% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$9.04
Open:
$8.7
24h Volume:
2.99M
Relative Volume:
3.26
Market Cap:
$450.91M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-2.948
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
-17.16%
1M Performance:
+26.13%
6M Performance:
+79.96%
1Y Performance:
+1.33%
1-Day Range:
$8.14
$9.0399
1-Week Range:
$8.14
$10.38
52-Week Range:
$1.45
$11.72
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
8.35 | 650.61M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | Guggenheim | Buy |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Is Lexeo Therapeutics Inc. meeting your algorithmic filter criteriaEarnings Trend Report & Long Hold Capital Preservation Plans - newser.com
Using data models to predict Lexeo Therapeutics Inc. stock movementJuly 2025 Momentum & Low Drawdown Momentum Ideas - newser.com
Using Python tools to backtest Lexeo Therapeutics Inc. strategiesQuarterly Earnings Report & Weekly Watchlist for Hot Stocks - newser.com
What to do if you’re stuck in Lexeo Therapeutics Inc.Market Risk Analysis & Weekly Watchlist of Top Performers - newser.com
Long term hold vs stop loss in Lexeo Therapeutics Inc.Gap Down & AI Driven Stock Reports - newser.com
How Lexeo Therapeutics Inc. stock reacts to bond yieldsEarnings Miss & Smart Allocation Stock Reports - newser.com
Can Lexeo Therapeutics Inc. stock withstand economic slowdown2025 Top Gainers & Verified Short-Term Trading Plans - newser.com
Using Ichimoku Cloud for Lexeo Therapeutics Inc. technicalsPortfolio Value Report & Real-Time Market Trend Scan - newser.com
Multi asset correlation models including Lexeo Therapeutics Inc.July 2025 Levels & Real-Time Chart Breakout Alerts - newser.com
Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim’s Stock Picks with Huge Upside Potential - Yahoo! Finance Canada
Will Lexeo Therapeutics Inc. price bounce be sustainableTrade Volume Summary & Verified Technical Trade Signals - newser.com
Using data filters to optimize entry into Lexeo Therapeutics Inc.Portfolio Return Summary & Verified Momentum Stock Ideas - newser.com
Will Lexeo Therapeutics Inc. stock outperform Nasdaq index2025 EndofYear Setup & Safe Capital Allocation Plans - newser.com
Should you hold or exit Lexeo Therapeutics Inc. nowWeekly Volume Report & Risk Managed Investment Strategies - newser.com
Why hedge funds are buying Lexeo Therapeutics Inc. stockEarnings Beat & High Conviction Buy Zone Picks - newser.com
Best data tools to analyze Lexeo Therapeutics Inc. stockGap Down & Weekly Return Optimization Plans - newser.com
Real time pattern detection on Lexeo Therapeutics Inc. stock2025 Growth vs Value & Fast Gain Stock Trading Tips - newser.com
Can Lexeo Therapeutics Inc. stock double in next 5 yearsJuly 2025 Opening Moves & Risk Controlled Swing Trade Alerts - newser.com
RA CAPITAL MANAGEMENT, L.P. Acquires 5 Million Shares in Lexeo T - GuruFocus
RA CAPITAL MANAGEMENT, L.P. Acquires 5 Million Shares in Lexeo Therapeutics Inc - GuruFocus
Risk vs reward if holding onto Lexeo Therapeutics Inc.Market Activity Recap & Real-Time Stock Entry Alerts - newser.com
Lexeo Therapeutics (LXEO) Price Target Increased by 19.77% to 21.29 - Nasdaq
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexeo Therapeutics Inc Stock (LXEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Robertson Jenny | Chief Legal Officer |
Oct 17 '25 |
Sale |
8.94 |
3,526 |
31,530 |
68,930 |
| Otero Jose Manuel | Chief Technical Officer |
Oct 17 '25 |
Sale |
8.94 |
2,115 |
18,913 |
64,197 |
| Adler Eric | Chief Medical Officer |
Oct 17 '25 |
Sale |
8.94 |
3,382 |
30,242 |
73,261 |
| Townsend Richard Nolan | Chief Executive Officer |
Oct 17 '25 |
Sale |
8.94 |
13,133 |
117,436 |
242,118 |
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):